title: How many patients will benefit from a new therapy for chronic systolic heart failure, and what difference does it make?
authors: Division of Cardiovascular Medicine, The Howard Gilman Institute for Heart Valve Disease, and the Schiavone Institute for Cardiovascular Translational Research, State University of New York Downstate Medical Center, Brooklyn and New York, New York. Electronic address: jsborer1@gmail.com.
authors: Jeffrey S
authors: JS
authors: Borer
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D001071:Appointments and Schedules; D001552:Benzazepines / Q000627:therapeutic use*; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D008297:Male; D010045:Outpatients
chemical_list: D000319:Adrenergic beta-Antagonists; D001552:Benzazepines
keywords: f-channels; heart rate reduction; myocardial function